
Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Your AI-Trained Oncology Knowledge Connection!


Published: February 18th 2017 | Updated: